E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Climate Change and Parasitic Diseases"

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: 1 December 2018

Special Issue Editors

Guest Editor
Prof. Mark Hamann

Drug Discovery and Biomedical Sciences, College of Pharmacy, Medical University of South Carolina, Charleston, SC, USA
Website | E-Mail
Interests: marine natural products chemistry; infectious diseases; cancer; spectroscopy; drug discovery and development
Guest Editor
Dr. Xiaoyan Chen

Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, SC, USA
Interests: natural products; medicinal plants; GI microbiome

Special Issue Information

Dear Colleagues,

Parasitic diseases, such as malaria, filariases, schistosomiasis, and Chagas disease continue to cause major health challenges for both human and agriculture health with particular challenges in tropical regions. Parasitic diseases are typically divided into three categories: Ectoparasites and two groups of endoparasites; protozoan and helminths. Malaria alone infects 300 million people each year and claims around a million lives. However, the treatments of these diseases remains limited and the currently available anti-parasitic drugs provide significant challenges in regard to drug resistance and adverse effects. Since the 1950s, a large number of secondary metabolites have been characterized from marine invertebrates, plants, and microbes, which possess vast structural diversity provided by the wealth of biodiversity found in the oceans. As a result marine natural products harbor great potential as controls of parasitic diseases and according to recent reports there are dozens of newly reported marine natural products showing anti-malarial, anti-leishmanial, and anti-trypanosomal activities with IC50 values of less than 15 μM. Advances in sample collection strategies, structure characterization, fermentation, metabolomics, assays screening and other related technologies continue to provide improvements in access to marine resources and advance the promise of marine-derived therapeutics for the control of parasitic diseases. Of course, the recent Nobel Prizes awarded to William Campbell, Satoshi Omura and Tu Youyou for their pioneering work in the development of treatments for roundworm parasites and malaria emphasizes the significance of discoveries to control parasitic diseases.

In this Special Issue of Marine Drugs we are encouraging investigators to provide preliminary communications, research papers and reviews covering the purification, structure determination, and biosynthetic pathways of compounds from marine origin with antiparasitic activity. In this compilation of papers we will also assess emerging technologies to facilitate the discovery and development of novel anti-parasitic agents as well as charactering mode of action. We would also encourage contributions that assess climate change and the impact climate change is having on both marine biodiversity as well as the global prevalence of parasitic diseases.

If you have specific questions about this Special Issue please feel free to contact us at 843-876-2316 or hamannm@musc.edu. You are also welcome to contact Ms. Melanie Yuan at the Marine Drugs Editorial Office (melanie.yuan@mdpi.com) or Dr. Chen at chenxi@musc.edu.

Prof. Mark Hamann
Dr. Xiaoyan Chen
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Antiparasitic agents
  • Marine Therapeutics
  • Tropical Neglected Diseases
  • Drug Discovery and Development
  • Natural Products Synthesis
  • Methodologies in Natural Products Discovery
  • Climate Change and Parasitic Diseases

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:


Open AccessReview Total Synthesis of Bioactive Marine Meroterpenoids: The Cases of Liphagal and Frondosin B
Mar. Drugs 2018, 16(4), 115; https://doi.org/10.3390/md16040115
Received: 22 February 2018 / Revised: 28 March 2018 / Accepted: 28 March 2018 / Published: 31 March 2018
PDF Full-text (5603 KB) | HTML Full-text | XML Full-text
Liphagal and frondosin B are two marine-derived secondary metabolites sharing a very similar polyfused-benzofuran skeleton. The two tetracyclic meroterpenoids were isolated from marine sponges, both featuring a 6-5-7-6 fused ring system. A preliminary bioactive study shows that (+)-liphagal is a selective kinase (PI3K
[...] Read more.
Liphagal and frondosin B are two marine-derived secondary metabolites sharing a very similar polyfused-benzofuran skeleton. The two tetracyclic meroterpenoids were isolated from marine sponges, both featuring a 6-5-7-6 fused ring system. A preliminary bioactive study shows that (+)-liphagal is a selective kinase (PI3K α) inhibitor, while (+)-frondosin B is shown to inhibit the binding of the cytokine interleukin-8 (IL-8) to its receptor, CX-CLR1/2. The unique structures and interesting biological profiles of these two meroterpenoids have attracted considerable attention from synthetic chemists. Herein we summarize the synthetic efforts with respect to (+)-liphagal and (+)-frondosin B during the past two decades. Full article
(This article belongs to the Special Issue Climate Change and Parasitic Diseases)

Figure 1

Back to Top